Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | WDR5 | P61964 | 4/20 | 0.49 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | FASN | P49327 | 2/20 | 0.49 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859243 | 0.98 | CYP2C9 (0.48) | KMT2ALMNACYP2C9WDR5ENGASE | |
| SCHEMBL8503283 | 0.96 | LMNA (0.47) | KMT2ALMNACYP2C9WDR5ENGASE | |
| SCHEMBL15797364 | 0.92 | KMT2A (0.49) | KMT2ALMNACYP2C9WDR5ENGASE | |
| SCHEMBL13360944 | 0.92 | KMT2A (0.47) | KMT2ALMNACYP2C9WDR5ENGASE | |
| SCHEMBL13361069 | 0.92 | KMT2A (0.47) | KMT2ALMNACYP2C9WDR5ENGASE | |
| SCHEMBL8503846 | 0.91 | KMT2A (0.58) | KMT2ALMNACYP2C9WDR5ENGASE | |
| Rabeprazole SCHEMBL23336 | 0.91 | KMT2A (0.61) | KMT2ALMNACYP2C9WDR5ENGASE | |
| SCHEMBL2983762 | 0.91 | CYP2C9 (0.48) | KMT2ALMNACYP2C9WDR5ENGASE | |
| SCHEMBL7988197 | 0.91 | CYP2C9 (0.48) | KMT2ALMNACYP2C9WDR5ENGASE | |
| Dexrabeprazole SCHEMBL4946138 | 0.91 | KMT2A (0.61) | KMT2ALMNACYP2C9WDR5ENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270555-B1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA SA (ES) | 2004-08-25 | — | — | EP | claimed |
| US-6603009-B2 | Oxidation of a thioether to a sulfoxide using sodium percarbonate and a molybdenum salt as catalyst; making lansoprazole, omeprazole, rabeprazole, and pantoprazole | ESTEVE QUIMICA, S.A. (ES) | 2003-08-05 | — | — | US | claimed |
| US-20030028030-A1 | Method for oxidizing a thioether group into a sulfoxide group | ESTEVE QUIMICA, S.A. (ES) | 2003-02-06 | — | — | US | claimed |
| EP-1270555-A1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA, S.A. (ES) | 2003-01-02 | — | — | EP | claimed |
| US-8992897-B2 | Skin lightening compositions | ELC MANAGEMENT LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | NIKI YOKO (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20100009003-A1 | PHARMACEUTICAL PREPARATION TO BE DISPERSED BEFORE ADMINISTRATION | UKAI KOJI | 2010-01-14 | — | — | US | disclosed |
| WO-2008035192-A2 | METHOD OF PREPARATION OF AMORPHOUS RABEPRAZOLE SODIUM | CADILA PHARMACEUTICALS LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008001392-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF PANTOPRAZOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2008-01-03 | — | — | WO | disclosed |
| EP-1270555-B1 | METHOD FOR OXIDIZING A THIOETHER GROUP INTO A SULFOXIDE GROUP | ESTEVE QUIMICA SA (ES) | 2004-08-25 | — | — | EP | disclosed |
| US-6603009-B2 | Oxidation of a thioether to a sulfoxide using sodium percarbonate and a molybdenum salt as catalyst; making lansoprazole, omeprazole, rabeprazole, and pantoprazole | ESTEVE QUIMICA, S.A. (ES) | 2003-08-05 | — | — | US | disclosed |
| US-5998445-A | PEPTIC ULCERS | EISAI CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| US-5840910-A | Pyridine derivatives having anti-ulcerative activity | ESAI CO., LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0268956-B2 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | EISAI CO LTD (JP) | 1998-04-15 | — | — | EP | disclosed |
| EP-0786461-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| EP-0654471-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and process for preparing the same | Eisai Co., Ltd. (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0475456-A1 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-5045552-A | Pyridine derivatives having anti-ulcerative activity | EISAI CO., LTD. (JP) | 1991-09-03 | — | — | US | disclosed |
| EP-0268956-A2 | Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same | Eisai Co., Ltd. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028030-A1 | Method for oxidizing a thioether group into a sulfoxide group | CBR1, CBR3, SCO2 | KMT2A 3015/4885LMNA 4429/4885CYP2C9 493/4885 |
| US-20140212365-A9 | SKIN LIGHTENING COMPOSITIONS | CUTA, TYR, DSG1 | KMT2A 1874/4885LMNA 212/4885CYP2C9 2552/4885 |
| US-20100009003-A1 | PHARMACEUTICAL PREPARATION TO BE DISPERSED BEFORE ADMINISTRATION | PGA5, SLC18A1, IL5 | KMT2A 4158/4885LMNA 1000/4885CYP2C9 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.